
Lupin to launch drug in USA that can fetch $200 million in FY26
Lupin shares rose 3% on April 23 after announcing the US launch of gTolvaptan, the generic version of Jynarque. With 180-day sole exclusivity starting today, Lupin is likely to be the only generic player through most of FY26. The drug could add $150–200 million in FY26 revenue, contributing over 25% to earnings and offsetting losses from gMirabegron.
Quicklinks